CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion
Cardiovascular Research · 28.10.2025 · 121 (13) · 2082-2094
DOI: 10.1093/cvr/cvaf165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 03.10.2025. Verfasst von Jonathan Noonan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia. Hauptthemen laut MEDLINE: Myocardial Infarction, Abatacept, Ventricular Function, Left, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council, NHF.
Abstract (Originalsprache)
Aims
T cells drive adverse cardiac inflammation and ischemia-reperfusion injury following myocardial infarction (MI). Here, we aimed to test the extent to which T cell inhibition protected cardiac function following MI in mice. Methods and results Cardiac ischemia-reperfusion injury (CIRI), mimicking MI with successful reperfusion therapy, was induced in C57BL/6J mice via temporary surgical ligation of the left anterior descending artery. T cell inhibition was achieved using abatacept, an FDA-approved CTLA-4-Ig fusion protein. Multiple treatment strategies were assessed, ranging from prolonged treatment across 4 weeks to short-term treatment, also with delayed time-to-intervention. Cardiac function was assessed using echocardiography, including strain analysis. Impacts on the cardiac and systemic immune response were assessed using flow cytometry. CIRI-induced robust CD4+ biased T cell activation in the heart within 7 days. Treatment with abatacept significantly preserved key echocardiographic metrics of cardiac function. This treatment coincided with near-complete inhibition of the cardiac T cell response, as well as reductions in innate inflammatory cells. Collectively, this demonstrated a central mechanistic role for T cell activation post-MI with reperfusion. Evaluation of short-term intervention strategies further demonstrated sustained preservation of cardiac function even where treatment was delayed by 24 h. Mechanistically, our data indicate that over 50% of lost cardiac function post-MI with reperfusion is T cell dependent.
Conclusion
T cell co-stimulation leading to activation is a central driver of the cardiac immune response following MI with reperfusion. The inhibition of this axis significantly protected against CIRI and preserved cardiac function. Ultimately, we highlight T cell immunomodulation and abatacept as highly promising approaches for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia.
- Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, VIC 3010, Australia.
- Department of Immunology, School of Translational Medicine, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia.
- Molecular Imaging and Nanotherapeutics Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia.
- Department of Medicine, School of Translational Medicine, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia.
- Department of Cardiology, The Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004, Australia.
ORCID-Profile: Jonathan Noonan, Nalin H Dayawansa, Andrew J Murphy, Daniel G Donner, Xiaowei Wang, Karlheinz Peter
Förderung
- Australian National Health and Medical Research Council
- NHF
Zitieren
APA
Noonan, J., Prijaya, S. A., Bienvenu, L. A., Dayawansa, N. H., Michla, M., Bongcaron, V., Sharma, P., Song, Y., Huang, A., Barbaro-Wahl, A., Huang, Y., Nguyen, H., Nguyen, A., Murphy, A. J., Zhang, Y., Lee, M. K. S., Johnson, C. J., Watson, A. M. D., Thomas, A. C., …, & Peter, K. (2025). CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion. Cardiovascular Research, 121(13), 2082-2094. https://doi.org/10.1093/cvr/cvaf165
Vancouver
Noonan J, Prijaya SA, Bienvenu LA, Dayawansa NH, Michla M, Bongcaron V, et al. CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion. Cardiovascular Research. 2025;121(13):2082-2094. doi:10.1093/cvr/cvaf165
BibTeX
@article{Noonan2025,
author = {Noonan, Jonathan and Prijaya, Shania A and Bienvenu, Laura A and Dayawansa, Nalin H and Michla, Marcel and Bongcaron, Viktoria and Sharma, Prerna and Song, Yuyang and Huang, Angela and Barbaro-Wahl, Anastasia and Huang, Yilu and Nguyen, Hung and Nguyen, Anne and Murphy, Andrew J and Zhang, Yiyu and Lee, Man K S and Johnson, Chad J and Watson, Anna M D and Thomas, Anita C and McFadyen, James D and Donner, Daniel G and Wang, Xiaowei and Peter, Karlheinz},
title = {CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion},
journal = {Cardiovascular Research},
year = {2025},
volume = {121},
number = {13},
pages = {2082--2094},
doi = {10.1093/cvr/cvaf165}
}
EUVIMED